Kenya to Establish First Biopharma Life Sciences Park at Konza Technopolis

Photo Caption: From left: Dr Wesley Rono, Chief Executive Officer of Kenya BioVax Institute; Dr Gerald Macharia, Board Chairman of Apifa Biotech; Franklin Keter, Chief Executive Officer of Apifa Biotech; Mercy Kiarie, representative of the Kenya-Sweden Partnership; John Paul Okwiri, Chief Executive Officer of Konza Technopolis Development Authority; and Sandeep Sinha, Senior Director and Head of Healthcare Consulting for the Middle East and Africa at JLL, during the signing of the grant agreement and consultancy contract for the proposed Biopharma Life Sciences Park in Nairobi.

NAIROBI, November 12,2026 – Kenya is set to establish its first Biopharma Life Sciences Park at Konza Technopolis following a funding commitment from Sweden’s development finance institution, Swedfund, to support preparatory studies for the proposed pharmaceutical manufacturing hub.

The project, spearheaded by Apifa Biotech in partnership with the Technopolis Development Authority (TDA) under a public-private partnership (PPP) framework, seeks to strengthen local production of medicines, vaccines and pharmaceutical ingredients while reducing the country’s reliance on imported health products.

Swedfund’s grant will finance technical and commercial assessments to establish the project’s feasibility, investment potential and implementation framework, paving the way for its next development phase.

The project has received approval from the National Treasury to proceed to the development phase, with the project committee selecting a consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare research and analytics company IQVIA to undertake the feasibility study.

Speaking during the grant agreement signing ceremony in Nairobi, Technopolis Development Authority Chief Executive Officer John Paul Okwiri said the project would fill a major gap in Konza Technopolis’ development strategy by establishing an anchor investment in its life sciences cluster.

“The Biopharma Life Sciences Park will position Konza as an emerging centre for life sciences and pharmaceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally,” said Okwiri.

He noted that the initiative demonstrated how public-private partnerships could mobilise private capital, technical expertise and other resources to deliver major infrastructure projects.

“Konza Technopolis is a strong champion of public-private partnerships because we believe they are the most practical way to move huge infrastructure from paper to reality. This project is a clear example of why private expertise and capital mobilisation matter,” he added.

Okwiri said Konza had already established the necessary infrastructure to attract investors, including reliable power, road networks, internet connectivity, sewerage and wastewater treatment facilities.

He observed that the proposed park would provide an integrated environment where pharmaceutical manufacturers could establish operations without having to independently invest in essential supporting infrastructure.

The CEO expressed confidence that the project would advance towards implementation, revealing that the authority hoped to break ground within the current financial year, ending June 2027.

He further explained that the facility would focus on active pharmaceutical ingredients (APIs), the essential components responsible for the therapeutic effects of medicines, alongside broader pharmaceutical manufacturing activities.

Apifa Biotech Board Chairman Gerald Macharia said the milestone marked significant progress towards establishing a pharmaceutical manufacturing ecosystem that would benefit Kenya and the wider East African region.

“We are grateful to the team at Konza and the PPP team at the Treasury for making it smoother for us to get to this point. Three years is actually a very short time to get this project where we are now,” said Macharia.

He said the proposed park would provide an integrated environment where pharmaceutical manufacturers could access essential infrastructure and facilities for production, research and development, and packaging.

Macharia observed that the initiative would also create opportunities for local investors and pharmaceutical companies to participate in the development of the country’s healthcare manufacturing industry.

“Any pharmaceutical manufacturer in the country right now does everything themselves, including looking for their own water and effluent management systems. This is an opportunity to come and plug and play, where everything has already been set up and established,” he said.

He added that the park would support the development of vaccines and other essential health products while strengthening the country’s capacity to meet growing healthcare demands.

Swedfund Health Sector Lead under its Project Accelerator programme, Elsa Ekblom, said the funding would strengthen project preparation and improve its attractiveness to long-term investors.

“This funding commitment we are making today will help to advance the necessary groundwork, strengthen project preparation, and create a clear pathway toward maximising national development outcomes and attracting long-term private investment to develop Kenya’s pharmaceutical and life sciences sector,” said Ekblom.

The proposed facility is expected to attract pharmaceutical manufacturers, researchers, investors and technology enterprises, creating an integrated ecosystem for innovation and industrial development.

The initiative aligns with the African Union’s ambition to meet 60 per cent of Africa’s health product needs through local manufacturing by 2040, as well as Kenya’s policy objective of producing at least half of its essential health products locally.

With the feasibility study set to assess the project’s technical requirements, commercial viability, investment structure and implementation roadmap, the initiative marks an important step towards positioning Kenya as a regional pharmaceutical and life sciences manufacturing destination.

Leave a Reply

Your email address will not be published. Required fields are marked *

You cannot copy content of this page